Colchicine, which may have some NLRP3 and IL-1β inhibitory effects, has shown efficacy in secondary prevention of cardiovascular events.60 Moreover, the role of IL-6 in CVD is being explored in ongoing trials of anti–IL-6 in patients with CAD and chronic kidney disease.61 In the CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study), patients with known CAD and above median hsCRP (high-sensitivity C-reactive protein) had decreased major adverse cardiac events and HF hospitalizations when treated with the neutralizing monoclonal anti–IL-1β canakinumab. This evidence concerns the gene NLRP3 and chronic kidney disease.